Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Jan N. Basile MD, FACP, FASH, FAHA

Professor of Medicine, Division of Cardiology, Medical University of South Carolina; Ralph H. Johnson VA Medical Center, Charleston, South Carolina

Jan Basile, MD, earned his medical degree in 1978 from the Medical College of Virginia in Richmond. He then completed his internship and residency at the Medical University of South Carolina (MUSC) in Charleston, where he was also Chief Resident. He is board certified in internal medicine and is a Fellow of the American College of Physicians (FACP), the American Society of Hypertension (FASH), and the American Heart Association (FAHA). For many years he served on the American Society of Hypertension (ASH) Board of Directors and has served within the AHA as Vice-Chair of Clinical Programs on the Council of Hypertension.

His honors and awards include the MUSC School of Medicine Excellence in Teaching award, the Golden Apple award, and, in 2014, he was the first recipient of the SC Department of Health and Environmental Control Hypertension Physician of the Year award. In 2019, he received the Marvin Moser Clinical Hypertension Award from the American Heart Association Council on Hypertension.

Dr. Basile’s research interests include outcome-based clinical trials involving hypertension, lipid disorders, and diabetes. He has been involved in many large hypertension trials including the ALLHAT, ACCOMPLISH, VALUE, ONTARGET, ACCORD and SPRINT and SPRINT-MIND trials most under the auspices of the NHLBI. Most recently he has been involved in diabetes outcome trials and trials studying the role of renal denervation (RDN) in the treatment of hypertension.

He continues to be a contributing author for the hypertension section of “Up To Date.”


Dr. Basile reports the following:
  • Research Grant  
    • ReCor (RADIANCE I and II)
    • Ablative Solutions: (Target BP I)
  • Consultant
    • Medtronic Adjudication Committee (AF-Hypertension Renal Denervation Study)
    • Eli Lilly (US SURPASS-CVOT Leader)
    • Up-to-Date (Hypertension Section)